G

ood morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

The Shire (SHPG) board is willing to recommend a sweetened $64 billion bid from Takeda Pharmaceutical (TKPYY) to shareholdersReuters reports. Some investors, however, worry that Takeda, with only $4.3 billion in cash on hand for the Shire deal, may be overreaching. Takeda stock initially fell more than 7 percent after the latest development was announced over doubts about whether Shire shareholders will accept a bid that is 56 percent in new Takeda shares. The companies received an extension from U.K. regulators until May 8 for Takeda to make a firm offer.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy